Mr. Paul Duffy reports

AIML SUBSIDIARY NEURALCLOUD SIGNS AGREEMENT WITH MYCOR360+ TO INTEGRATE MAXYIELD INTO NEXT-GENERATION CARDIAC MONITORING DEVICE

AI-ML Innovations Inc.'s wholly owned subsidiary, NeuralCloud Solutions Inc., has entered into a non-binding agreement with MyCor360+, a cardiac monitoring technology initiative developing a new medical device platform, to explore the integration and licensing of NeuralCloud's proprietary MaxYield ECG signal processing technology.

The proposed collaboration is focused on incorporating MaxYield as the software intelligence layer within a cardiac monitoring device currently under development. The objective is to combine advanced ECG recording hardware with NeuralCloud's artificial-intelligence-powered signal processing capabilities to support more efficient and detailed ECG analysis for clinical applications.

Under the proposed arrangement, MyCor360+ will oversee the development and commercialization of the device through its manufacturing partner while NeuralCloud will provide its MaxYield technology for integration into the platform. The parties intend to pursue a definitive software licensing agreement following further technical development and satisfaction of applicable regulatory requirements.

Combining ECG hardware with AI-powered signal processing

Cardiac monitoring continues to evolve as health care providers seek technologies that can deliver high-quality ECG data, support efficient diagnostic workflows and enable longer-duration monitoring outside of traditional clinical settings.

MyCor360+ is developing a cardiac monitoring platform intended to bring together ECG recording hardware and advanced software capabilities within an integrated solution.

MaxYield is NeuralCloud's proprietary AI-based ECG signal processing engine designed to improve signal clarity, reduce noise and artifacts, and identify and label key ECG waveform components, including P waves, QRS complexes and T waves. The platform generates structured, machine-readable outputs, including waveform delineation and beat-level interval measurements, to support downstream ECG analysis and reporting workflows.

By incorporating MaxYield directly into the proposed cardiac monitoring platform, the parties aim to evaluate a combined hardware and software solution capable of providing cleaner, more detailed ECG data for use in cardiac monitoring applications.

Developing an integrated cardiac monitoring solution

MyCor360+ is developing a cellular-enabled cardiac monitoring device intended to support both traditional Holter monitoring and mobile cardiac telemetry applications. The proposed device is being designed as a disposable, single-use solution capable of recording cardiac activity for up to 14 days, with automated transmission of ECG data through cellular networks.

The planned technology is intended to address several limitations of conventional cardiac monitoring devices by simplifying the patient experience, reducing dependence on manual data transfers, and enabling more efficient access to recorded ECG information. Where cellular connectivity is temporarily unavailable, the system is being designed to retain recorded data for transmission once connectivity is restored.

The proposed platform will also include a streamlined clinician-facing portal for managing ECG recordings and supporting integration with existing health care workflows and electronic medical record systems. NeuralCloud's MaxYield technology is expected to provide the underlying AI-powered signal processing capabilities, converting recorded ECG signals into cleaner, structured data for downstream analysis and reporting.

Together, the parties aim to develop a more integrated approach to ambulatory cardiac monitoring, combining convenient ECG acquisition, automated data transmission and advanced signal processing within a unified workflow.

Esmat Naikyar, president of NeuralCloud and chief product officer of AI-ML, commented: "Cardiac monitoring technology is evolving rapidly, and there is growing demand for solutions that combine reliable ECG acquisition with intelligent signal processing. MaxYield was designed to address one of the fundamental challenges in ECG analysis: separating meaningful cardiac signals from noise while preserving detailed waveform information. This collaboration provides an opportunity to integrate that capability into a new cardiac monitoring platform and evaluate its potential to support more efficient and informative ECG analysis."

Advancing NeuralCloud's original equipment manufacturing integration strategy

The proposed collaboration supports NeuralCloud's broader strategy to expand the reach of MaxYield through partnerships with medical device developers, original equipment manufacturers and cardiac monitoring technology providers.

Rather than requiring hardware manufacturers to independently develop sophisticated ECG signal processing algorithms, MaxYield is designed to provide an AI-powered software layer that can be incorporated into compatible devices and digital health platforms.

This approach allows NeuralCloud to focus on its core expertise in ECG signal interpretation while collaborating with partners responsible for hardware development, manufacturing and device distribution.

Paul Duffy, executive chairman and chief executive officer of AI-ML, commented: "This agreement reflects our continued efforts to establish MaxYield as a core signal processing technology for the cardiac monitoring industry. By combining our AI capabilities with a developing cellular-enabled Holter and mobile cardiac telemetry platform, we see an opportunity to support a more seamless cardiac monitoring experience for patients and health care providers. This collaboration aligns with our broader strategy of integrating MaxYield directly into next-generation medical devices."

Next steps and regulatory considerations

The parties expect to work toward technical co-ordination between NeuralCloud and MyCor360+'s manufacturing partner to evaluate the proposed integration of MaxYield into the developing device platform.

The collaboration remains at an early stage, and the agreement is non-binding. Any definitive commercial arrangement, software deployment or product commercialization will be subject to further agreement between the parties, successful technical integration and applicable regulatory requirements.

Neither MaxYield nor the MyCor360+ device has received Food and Drug Administration clearance for the proposed application. Implementation of the contemplated commercial licensing arrangement is subject to the required FDA clearances for the hardware and MaxYield software, as well as confirmation of technical readiness. The agreement does not constitute regulatory clearance, marketing authorization or a commitment to commercial deployment.

About AI-ML Innovations Inc.

AI-ML Innovations is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. The company's proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights -- supporting earlier diagnosis, personalized treatment and more effective care.

AI-ML's shares trade on the Canadian Securities Exchange (AIML), the OTCQB Venture Market (AIMLF) and the Frankfurt Stock Exchange (42FB).

We seek Safe Harbor.